This is the authors' abstract. We don't add key points for this paper.
The development of biologic drugs (recombinant proteins, therapeutic antibodies, peptides, nucleic acid therapeutics) as new treatments of brain disorders has been difficult, and a major reason is the lack of transport through the blood-brain barrier (BBB) of these large molecule pharmaceuticals. Biologic drugs can be re-engineered as brain-penetrating neuropharmaceuticals using BBB molecular Trojan horse technology. Certain peptidomimetic monoclonal antibodies that target endogenous receptors on the BBB, such as the insulin or transferrin receptor, enable the re-engineering of biologic drugs that cross the BBB.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
William M. Pardridge (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: